Lupin Limited announced on Thursday the launch of its generic cancer treatment drug in the US market. The Mumbai-based pharmaceutical firm has introduced Doxorubicin Hydrochloride Liposome Injection in single-dose vials. This launch follows the approval from the US Food and Drug Administration (FDA) received by Lupin’s
Global pharma major Lupin Limited (Lupin) today announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded
Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynd® Tablets, 4 mg, of Exeltis USA Inc. Drospirenone
